Clinical trial · Observational
Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma
Prospective Randomized Trial for the Evaluation of a Theoretical Follow-Up Schedule in Cutaneous Melanoma Patients, the MELFO-Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Gathering information over time from follow-up visits may help doctors plan the best follow-up schedule. It is not yet known which follow-up schedule is more effective in improving patient quality of life. PURPOSE: This randomized clinical trial is comparing follow-up schedules to see how well they work in patients with newly diagnosed stage IB or stage II melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| follow-up care | Other | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
| questionnaire administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Patient well-being expressed in 4 questionnaires
Secondary outcomes (4)
- measure
- Occurrence and type of recurrence (locoregional versus distant metastases) that develop
- measure
- Person detecting the recurrences and the exact way of detection
- measure
- Progress of recurrent disease and consequences for its treatment
- measure
- Well-being of patients per group and of recurred patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Pathologically confirmed newly diagnosed cutaneous melanoma * AJCC stage IB or II disease * Received curative treatment * Completed the first set of questionnaires PATIENT CHARACTERISTICS: * Able to speak and understand Dutch or English * Must be able to participate in the follow-up schedule (e.g., permanently living in the Netherlands) * No known second malignancy PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available